Dogwood reports Q2 2026 results as Halneuron Phase 2b nears fall readout
Dogwood Therapeutics said its 217-patient Halneuron Phase 2b trial in chemotherapy-induced neuropathic pain remains on track for top-line data in fall 2026, with cash of $9.6 million.
Dogwood Therapeutics announced second quarter 2026 results on August 13, 2026. The company said it currently has enrolled 217 patients in its Halneuron Phase 2b Chemotherapy Induced Neuropathic Pain study, with top-line results readout expected in the fall of 2026.1
The company also disclosed that Dogwood commenced a Phase 2b long-term extension study to assess Halneuron's reduction in pain over three months of treatment, and patients completing the ongoing Halneuron 4-week CINP Phase 2b study are now eligible to enroll in the new 12-week open-label follow-on trial.1
On the regulatory side, SP16 was granted IND approval from the FDA, with the study expected to begin enrolling in the second half of 2026 for treatment of chemotherapy induced pain and peripheral neuropathy; the study is fully funded by the National Cancer Institute and will be conducted at the University of Virginia.1
Dogwood also said it appointed Iain Dukes, D.Phil., Venture Partner at OrbiMed, as Chair of its Scientific Advisory Board.1
On cash, the company reported cash on hand of $9.6 million, which it said provides operational runway through the Phase 2b readout in the fourth quarter of 2026.1
The release also noted a partnership development: the company announced a worldwide development and commercialization partnership for legacy antiviral assets with potential value up to $100 million to Dogwood and its CVR holders.1 Per the CVR terms, any Upfront Payment or Milestone Payment under the CVRs issued October 17, 2024 will be delivered to the rights agent for further payment to CVR holders.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.